# US 2008/0188413 A1 · Disintegrin variants and pharmaceutical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188413 A1
- Document ID: US20080188413A1
- Status: Published application
- Kind: A1
- Application number: 12/004,045
- Filed: 2007-12-20
- Published: 2008-08-07
- Earliest claimed: 2006-12-26
- Assignees: National Cheng Kung University; National Taiwan University
- Inventors: Woei-Jer Chuang; Wen-Mei Fu; Tur-Fu Huang; Wenya Huang; Chih-Hsin Tang; Chiu-Yueh Chen
- Web page: https://patentgrep.com/patent/US20080188413A1

## CPC

- C07K 14/46: from vertebrates
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/745: Blood coagulation or fibrinolysis factors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and/or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin αllbβ3 and/or α5β1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of αvβ3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.

## Claims

### Claim 1

A method for treatment and/or prevention of an αvβ3 integrin-associated disease comprising:
administering to a mammal in need thereof a therapeutically effective amount of a polypeptide, or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises a disintegrin variant that is selective for αvβ3 integrin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disintegrin is a variant of a disintegrin chosen from rhodostomin, albolabrin, applagin, basilicin, batroxostatin, bitistatin, cereberin, cerastin, crotatroxin, durissin, elegantin, flavoridin, flavostatin, halysin, halystatin, jararacin, jarastatin, kistrin, lachesin, lutosin, molossin, salmosin, saxatilin, tergeminin, trimestatin, trimucrin, trimutase, ussuristatin, and viridin.

### Claim 3 (depends on 2)

The method of claim 2, wherein the disintegrin variant comprises a variant of rhodostomin.

### Claim 4 (depends on 3)

The method of claim 3, wherein said rhodostomin variant comprises a variant of the amino acid sequence of SEQ ID NO: 1.

### Claim 5 (depends on 4)

The method of claim 4, wherein said rhodostomin variant comprises an amino acid sequence chosen from SEQ ID NOs: 30-42.

### Claim 6 (depends on 4)

The method of claim 4, wherein said rhodostomin variant comprises an amino acid sequence chosen from SEQ ID NOs: 57-69.

### Claim 7 (depends on 1)

The method of claim 1, wherein said polypeptide is pegylated or conjugated with albumin.

### Claim 8 (depends on 1)

The method of claim 1, wherein the αvβ3 integrin-associated disease is chosen from osteoporosis, bone tumor or cancer growth and symptoms related thereto, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye disease, Paget's disease, rheumatic arthritis, and osteoarthritis.

### Claim 9 (depends on 8)

The method of claim 8, wherein the angiogenesis-related eye disease is chosen from age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.

### Claim 10 (depends on 8)

The method of claim 8, wherein the αvβ3 integrin-associated disease comprises osteoporosis.

### Claim 11 (depends on 10)

The method of claim 10, wherein said osteoporosis is associated with a pathological condition chosen from post-menopausal estrogen deficiency, secondary osteoporosis, ovariectomy, Paget's disease, bone cancer, bone tumor, osteoarthritis, increased osteoclast formation, and increased osteoclast activity.

### Claim 12 (depends on 11)

The method of claim 11, wherein the osteoporosis comprises post-menopausal osteoporosis or bone loss.

### Claim 13 (depends on 1)

The method of claim 1, wherein the mammal is a human.

### Claim 14

A method for treatment and/or prevention of an ovariectomy-induced physiological change comprising:
administering to a mammal in need thereof a therapeutically effective amount of a polypeptide, or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises a disintegrin variant that is selective for αvβ3 integrin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disintegrin is a variant of a disintegrin chosen from rhodostomin, albolabrin, applagin, basilicin, batroxostatin, bitistatin, cereberin, cerastin, crotatroxin, durissin, elegantin, flavoridin, flavostatin, halysin, halystatin, jararacin, jarastatin, kistrin, lachesin, lutosin, molossin, salmosin, saxatilin, tergeminin, trimestatin, trimucrin, trimutase, ussuristatin, and viridin.

### Claim 16 (depends on 15)

The method of claim 15, wherein the disintegrin variant comprises a variant of rhodostomin.

### Claim 17 (depends on 16)

The method of claim 16, wherein said rhodostomin comprises a variant of the amino acid sequence of SEQ ID NO: 1.

### Claim 18 (depends on 17)

The method of claim 17, wherein said rhodostomin variant comprises an amino acid sequence chosen from SEQ ID NOs: 30-42.

### Claim 19 (depends on 17)

The method of claim 17, wherein said rhodostomin variant comprises an amino acid sequence chosen from SEQ ID NOs: 57-69.

### Claim 20 (depends on 14)

The method of claim 14, wherein said polypeptide is pegylated or conjugated with albumin.

### Claim 21 (depends on 14)

The method of claim 14, wherein the mammal is a human.

### Claim 22

A method for inhibition and/or prevention of tumor cell growth in bone and symptoms related thereto comprising:
administering to a mammal in need thereof a therapeutically effective amount of a polypeptide, or a pharmaceutically acceptable salt thereof, wherein the polypeptide comprises a disintegrin variant that is selective for αvβ3 integrin.

### Claim 23 (depends on 22)

The method of claim 22, wherein the disintegrin is a variant of a disintegrin chosen from rhodostomin, albolabrin, applagin, basilicin, batroxostatin, bitistatin, cereberin, cerastin, crotatroxin, durissin, elegantin, flavoridin, flavostatin, halysin, halystatin, jararacin, jarastatin, kistrin, lachesin, lutosin, molossin, salmosin, saxatilin, tergeminin, trimestatin, trimucrin, trimutase, ussuristatin, and viridin.

### Claim 24 (depends on 23)

The method of claim 23, wherein the disintegrin variant comprises a variant of rhodostomin.

### Claim 25 (depends on 24)

The method of claim 24, wherein said rhodostomin variant comprises a variant of SEQ ID NO: 1.

### Claim 26 (depends on 25)

The method of claim 25, wherein said rhodostomin variant comprises amino acid sequence chosen from SEQ ID NOs: 30-42.

### Claim 27 (depends on 25)

The method of claim 25, wherein said rhodostomin variant comprises an amino acid sequence chosen from SEQ ID NOs: 57-69.

### Claim 28 (depends on 22)

The method of claim 22, wherein said polypeptide is pegylated or conjugated with albumin.

### Claim 29 (depends on 22)

The method of claim 22, wherein said symptoms comprise a pathological symptom chosen from an increased osteoclast activity, increased bone resorption, bone lesion, hypercalcemia, a body weight loss, and any combinations thereof.

### Claim 30 (depends on 22)

The method of claim 22, wherein the tumor cell growth in bone includes bone cancer cells, and metastasized cancer cells originating from one or more of prostate cancer, breast cancer, lung cancer, thyroid cancer, renal cancer, ovarian cancer, pancreatic cancer, and myeloma cancer.

### Claim 31 (depends on 22)

The method of claim 22, wherein the mammal is a human.

### Claim 32

A polypeptide selective for αvβ3 integrin, wherein the polypeptide is a variant of a disintegrin.

### Claim 33 (depends on 32)

The polypeptide of claim 32, wherein the disintegrin is a variant of a disintegrin chosen from rhodostomin, albolabrin, applagin, basilicin, batroxostatin, bitistatin, cereberin, cerastin, crotatroxin, durissin, elegantin, flavoridin, flavostatin, halysin, halystatin, jararacin, jarastatin, kistrin, lachesin, lutosin, molossin, salmosin, saxatilin, tergeminin, trimestatin, trimucrin, trimutase, ussuristatin, and viridin.

### Claim 34 (depends on 32)

The polypeptide of claim 32, wherein the disintegrin comprises a variant of rhodostomin.

### Claim 35 (depends on 32)

The polypeptide of claim 32, wherein said rhodostomin variant comprises a variant of SEQ ID NO: 1.

### Claim 36 (depends on 35)

The polypeptide of claim 35, wherein said rhodostomin variant comprises an amino acid sequence chosen from SEQ ID NOs: 30-42.

### Claim 37 (depends on 32)

A polypeptide of claim 32, wherein said rhodostomin variant comprises the amino acids sequence of SEQ ID NO: 29 and comprises at least one amino acid substitution in a position chosen from positions 48, 50, 52, or 53 of SEQ ID NO: 1.

### Claim 38 (depends on 37)

The polypeptide of claim 37, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, Ile, and His at position 50, Asp, Met, and Asn at position 52, and Val, Leu, and Met at position 53.

### Claim 39 (depends on 38)

The polypeptide of claim 38, wherein the amino acid substitution is at position 50 or 52.

### Claim 40 (depends on 37)

The polypeptide of claim 37, wherein the polypeptide comprises amino acid substitutions in at least two positions chosen from positions 48, 50, 52, and 53 of SEQ ID NO: 1.

### Claim 41 (depends on 40)

The polypeptide of claim 40, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, Ile, and His at position 50, Asp, Met, and Asn at position 52, and Val, Leu, and Met at position 53.

### Claim 42 (depends on 41)

The polypeptide of claim 41, wherein the amino acid substitutions are at positions 48 and 52.

### Claim 43 (depends on 41)

The polypeptide of claim 41, wherein the amino acid substitutions are at positions 52 and 53.

### Claim 44 (depends on 37)

The polypeptide of claim 37, wherein the polypeptide comprises amino acid substitutions in at least three positions chosen from positions 48, 50, 52, and 53 of SEQ ID NO: 1.

### Claim 45 (depends on 44)

The polypeptide of claim 44, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, Ile, and His at position 50, Asp, Met, and Asn at position 52, and Val, Leu, and Met at position 53.

### Claim 46 (depends on 45)

The polypeptide of claim 45, wherein the amino acid substitutions are at positions 48, 52, and 53.

### Claim 47 (depends on 45)

The polypeptide of claim 45, wherein the amino acid substitutions are at positions 50, 52, and 53.

### Claim 48 (depends on 37)

The polypeptide of claim 37, wherein the polypeptide comprises amino acid substitutions in at least four positions chosen from positions 48, 50, 52, and 53 of SEQ ID NO: 1.

### Claim 49 (depends on 48)

The polypeptide of claim 48, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, lie, and His at position 50, Asp, Met, and Asn at position 52, and Val, Leu, and Met at position 53.

### Claim 50 (depends on 32)

The polypeptide of claim 32, wherein said polypeptide is encoded by a polynucleotide comprising a nucleotide sequence chosen from SEQ ID NOs: 43-56.

### Claim 51 (depends on 32)

The polypeptide of claim 32, wherein said polypeptide exhibits at least about a 5, 50, or 100-fold decrease in affinity to αllbβ3 and/or α5β1 as compared to rhodostomin.

### Claim 52 (depends on 32)

The polypeptide of claim 32, wherein said polypeptide exhibits at least about a 200-fold decrease in affinity to αllbβ3 and/or α5β1 as compared to rhodostomin.

### Claim 53 (depends on 32)

The polypeptide of claim 32, wherein said polypeptide exhibits at least about a 1000, or 2000-fold decrease in affinity to αllbβ3 and/or α5β1 as compared to rhodostomin.

### Claim 54 (depends on 32)

The polypeptide of claim 32, wherein said polypeptide exhibits at least about 5, 50, 100, 1000, or 2000-fold decrease in affinity to platelet as compared to rhodostomin.

### Claim 55 (depends on 32)

The polypeptide of claim 32, wherein said polypeptide exhibits reduced activity in prolongation of blood clotting time as compared to rhodostomin.

### Claim 56 (depends on 32)

The polypeptide of claim 32, wherein said polypeptide is pegylated or conjugated with albumin.

### Claim 57 (depends on 37)

A physiologically acceptable composition comprising the polypeptide of claim 37 and a pharmaceutically acceptable carrier.

### Claim 58 (depends on 40)

A physiologically acceptable composition comprising the polypeptide of claim 40 and a pharmaceutically acceptable carrier.

### Claim 59 (depends on 44)

A physiologically acceptable composition comprising the polypeptide of claim 44 and a pharmaceutically acceptable carrier.

### Claim 60 (depends on 48)

A physiologically acceptable composition comprising the polypeptide of claim 48 and a pharmaceutically acceptable carrier.

### Claim 61 (depends on 50)

A physiologically acceptable composition comprising the polypeptide of claim 50 and a pharmaceutically acceptable carrier.

### Claim 62 (depends on 57)

The physiologically acceptable composition of claim 57, wherein said polypeptide is pegylated or conjugated with albumin.

### Claim 63

A polypeptide comprising an amino acid sequence chosen from SEQ ID NOs: 57-69.

### Claim 64 (depends on 32)

A method for making a polypeptide according to claim 32, comprising the steps of:
a. transfecting a host cell with a polynucleotide encoding said polypeptide;
b. growing said host cell in a culture medium; and
c. isolating said polypeptide.

### Claim 65 (depends on 64)

The method of claim 64, wherein (b) further comprises adding methanol to said culture medium.

### Claim 66 (depends on 64)

The method of claim 64, further comprising growing the host cell in a culture medium free of amino acids.

### Claim 67 (depends on 64)

The method of claim 64, wherein (c) further comprises performing a column chromatography to obtain said polypeptide.

### Claim 68 (depends on 64)

The method of claim 64, further comprising performing a HPLC to obtain said polypeptide.

### Claim 69 (depends on 64)

The method of claim 64, wherein said host cell is a yeast cell.

### Claim 70

A polynucleotide encoding a polypeptide selective for αvβ3 integrin, wherein the polypeptide is a variant of a disintegrin.

### Claim 71 (depends on 70)

The polynucleotide of claim 70, wherein the disintegrin is a variant of a disintegrin chosen from rhodostomin, albolabrin, applagin, basilicin, batroxostatin, bitistatin, cereberin, cerastin, crotatroxin, durissin, elegantin, flavoridin, flavostatin, halysin, halystatin, jararacin, jarastatin, kistrin, lachesin, lutosin, molossin, salmosin, saxatilin, tergeminin, trimestatin, trimucrin, trimutase, ussuristatin, and viridin.

### Claim 72 (depends on 70)

The polynucleotide of claim 70, wherein the disintegrin comprises a variant of rhodostomin.

### Claim 73 (depends on 72)

The polynucleotide of claim 72, wherein said rhodostomin variant comprises a variant of SEQ ID NO: 1.

### Claim 74 (depends on 73)

The polynucleotide of claim 73, wherein said disintegrin variant comprises an amino acid sequence chosen from SEQ ID NOs: 30-42.

### Claim 75 (depends on 70)

The polynucleotide of claim 70, wherein said rhodostomin variant comprises the amino acids sequence of SEQ ID NO: 29 and comprises at least one amino acid substitution in a position chosen from positions 48, 50, 52, or 53 of SEQ ID NO: 1.

### Claim 76 (depends on 75)

The polynucleotide of claim 75, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, Ile, and His at position 50, Asp, Met, and Asn at position 52, and Val, Leu, and Met at position 53.

### Claim 77 (depends on 76)

The polynucleotide of claim 76, wherein the amino acid substitution is at position 50 or 52.

### Claim 78 (depends on 75)

The polynucleotide of claim 75, wherein the polypeptide comprises amino acid substitutions in at least two positions chosen from positions 48, 50, 52, and 53 of SEQ ID NO: 1.

### Claim 79 (depends on 78)

The polynucleotide of claim 78, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, lie, and His at position 50, Asp, Met, and Asn at position 52, and Val, Leu, and Met at position 53.

### Claim 80 (depends on 79)

The polynucleotide of claim 79, wherein the amino acid substitutions are at positions 48 and 52.

### Claim 81 (depends on 79)

The polynucleotide of claim 79, wherein the amino acid substitutions are at positions 52 and 53.

### Claim 82 (depends on 75)

The polynucleotide of claim 75, wherein the polypeptide comprises amino acid substitutions in at least three positions chosen from positions 48, 50, 52, and 53 of SEQ ID NO: 1.

### Claim 83 (depends on 82)

The polynucleotide of claim 82, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, lie, and His at position 50, Asp, Met, and Asn at position 42, and Val, Leu, and Met at position 53.

### Claim 84 (depends on 83)

The polynucleotide of claim 83, wherein the amino acid substitutions are at positions 48, 52, and 53.

### Claim 85 (depends on 83)

The polynucleotide of claim 83, wherein the amino acid substitutions are at positions 50, 52, and 53.

### Claim 86 (depends on 75)

The polynucleotide of claim 75, wherein the polypeptide comprises amino acid substitutions in at least four positions chosen from positions 48, 50, 52, and 53 of SEQ ID NO: 1.

### Claim 87 (depends on 86)

The polynucleotide of claim 86, wherein the amino acid substitutions are chosen from Ala at position 48, Leu, Ile, and His at position 50, Asp, Met, and Asn at position 42, and Val, Leu, and Met at position 53.

### Claim 88 (depends on 70)

The polynucleotide of claim 70, wherein the polynucleotide comprises a sequence chosen from SEQ ID NOs: 43-56 and 78-135.

### Claim 89 (depends on 37, 70)

The polynucleotide of claim 70, wherein the polynucleotide encodes the polypeptide of claim 37.

### Claim 90 (depends on 40)

The polynucleotide encoding a polypeptide selective for αvβ3 integrin, wherein the polypeptide is a variant of integrin and wherein the polynucleotide encodes the polypeptide of claim 40.

### Claim 91 (depends on 44)

The polynucleotide encoding a polypeptide selective for αvβ3 integrin, wherein the polypeptide is a variant of integrin and wherein the polynucleotide encodes the polypeptide of claim 44.

### Claim 92 (depends on 48)

The polynucleotide encoding a polypeptide selective for αvβ3 integrin, wherein the polypeptide is a variant of integrin and wherein the polynucleotide encodes the polypeptide of claim 48.

### Claim 93 (depends on 50)

The polynucleotide encoding a polypeptide selective for αvβ3 integrin, wherein the polypeptide is a variant of integrin and wherein the polynucleotide encodes the polypeptide of claim 50.

### Claim 94 (depends on 73)

A polynucleotide that hybridizes under stringent conditions to the polynucleotide of claim 73.

### Claim 95 (depends on 94)

A polypeptide encoded by the nucleotide of claim 94.
